Bristol-Myers Squibb completes acquisition of iPierian Bristol-Myers Squibb Company and iPierian, Inc. Announced today that Bristol-Myers Squibb has acquired iPierian, a privately kept biotechnology company centered on the discovery and advancement of new remedies for Tauopathies, a class of neurodegenerative diseases associated with the pathological aggregation of Tau protein in the human brain. The acquisition gives Bristol-Myers Squibb full rights to iPierian's lead asset IPN007, a forward thinking preclinical monoclonal antibody that represents a promising new approach to deal with progressive supranuclear palsy and other Tauopathies, and has the potential to commence Stage 1 clinical trials by early 2015 buy equipoise http://boldenone-300.com .

www.boldenone-300.com

15 % of most strokes are attributable to AF, and 1 quarter of all strokes in persons over the age of 80 years are attributable to AF. Furthermore to treatments for heartrate and rhythm, treatment guidelines recommend that AF patients in moderate to risky of stroke receive anticoagulation therapy with a vitamin K antagonist , such as warfarin. However, surveys of practice patterns in developed countries demonstrate that 40 % to 50 % of individuals with AF who are at moderate or high risk for stroke do not receive VKA. The most common reason behind not treating AF individuals with a VKA is apparently concern about bleeding.

.

Other Posts From Category "psychology":

Related Posts